Recent research confirmed the utility of methylation markers, including boule homolog (BOLL), DCC netrin 1 receptor (DCC), and SFRP2, for monitoring neoadjuvant chemotherapy response in CRC patients with liver metastases [118, 119]. This evidence concerns the gene DCC and colorectal carcinoma.